ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1343

A Quality Improvement Initiative to Improve Pneumococcal Vaccination Rates in Immunosuppressed Patients

Melissa Bussey1 and Rochella A. Ostrowski2, 1Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, 2Rheumatology, Loyola University Medical Center, Maywood, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Quality improvement and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Quality of Care

Session Type: Abstract Submissions (ACR)

Background/Purpose   

Patients with autoimmune diseases are at increased risk of complicated infections, and immunomodulating treatment regimens further enhance this risk.  Many of these infections, including influenza, invasive pneumococcal disease, herpes zoster, and human papillomavirus, are vaccine preventable.  The Centers for Disease Control (CDC), American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) recommend pneumococcal vaccination for patients who are immunosuppressed.  Despite these clear recommendations, studies have shown pneumococcal vaccination rates ranging from only 19-54% in immunosuppressed populations.  The aim of this study was to evaluate the effect of an educational intervention and distribution of a pocket vaccination guide on pneumococcal vaccination rates in an academic rheumatology practice.

Methods  

Six attending rheumatologists in an academic setting were selected to receive the intervention in the form of an oral PowerPoint presentation and a pocket-sized guide containing CDC guidelines for vaccination, ACR recommendations regarding the use of vaccines in patients with rheumatoid arthritis, and the most recent recommendations for the pneumococcal vaccine including indications for the pneumococcal conjugate vaccine (PCV13).  The rates of immunosuppressed patients being up-to-date with pneumococcal vaccination were assessed pre- and post-intervention over a one month time period (August 2012 and August 2013).  Up-to-date vaccination status was defined as any one vaccine dose over age 65, any one dose in the last 5 years, or any 2 prior doses 5 years apart.  Only patients age 18 and older on immunosuppressive therapy who were being seen on a follow up basis were included.  Patients receiving rituximab were excluded as it is thought to decrease vaccine efficacy.  Chi-square test and logistic regression were used to analyze the data (STATA 11.0).

Results  

Among all providers, 171 immunosuppressed patients were seen in the pre-intervention time period and 190 in the post-intervention time period.  19.9% of eligible immunosuppressed patients were up-to-date with their pneumococcal vaccination pre-intervention as compared to 31.6% post-intervention (p=0.003) with an odds ratio of 1.85 (95% CI 1.11-3.01)[Table 1].  This increase remained significant when adjusting for site of clinic and provider.  Among patients less than 65 years old, up-to-date vaccination status increased from 7.9% pre-intervention to 25.9% post-intervention (p<0.0005).  Vaccination practices varied widely among providers.

Conclusion  

A QI strategy involving an educational session along with distribution of a pocket-sized vaccination guide significantly increased the rate of being up-to-date with pneumococcal vaccination among immunosuppressed patients in our academic rheumatology practice.


Disclosure:

M. Bussey,
None;

R. A. Ostrowski,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-quality-improvement-initiative-to-improve-pneumococcal-vaccination-rates-in-immunosuppressed-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology